ArticleiScience2025

Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors.

Shaoyan Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.